High-Dose Aumolertinib for Untreated EGFR-Variant Non–Small Cell Lung Cancer With Brain Metastases

医学 内科学 实体瘤疗效评价标准 肺癌 临床终点 肿瘤科 脑转移 无进展生存期 癌症 临床试验 化疗 进行性疾病 转移
作者
Hui Li,Kaiyan Chen,Lei Gong,Jing Qin,Ying Jin,Rongrong Zhou,Zhiyu Huang,Yanjun Xu,Xiaoling Xu,Jingdong He,Junfei Zhu,Sizhe Yu,Hongyang Lu,Yujin Xu,Xiaoling Yu,Guang Han,Jun Chen,Wei Tan,Guangyuan Lou,Biyong Ren
出处
期刊:JAMA Oncology [American Medical Association]
卷期号:11 (8): 900-900 被引量:9
标识
DOI:10.1001/jamaoncol.2025.1779
摘要

Importance: Central nervous system (CNS) metastases remain a significant challenge in the management of EGFR-variant non-small cell lung cancer (NSCLC). Objective: To evaluate the activity and safety of high-dose aumolertinib in patients with untreated EGFR-variant NSCLC and brain metastases. Design, Setting, and Participants: This was a phase 2 nonrandomized clinical trial conducted at 10 centers in China. Patients with untreated EGFR-variant metastatic NSCLC and brain metastases were enrolled between July 6, 2021, and August 31, 2022. The data cutoff date was October 10, 2024. Interventions: Patients received aumolertinib, 165 mg, orally once daily until disease progression or unacceptable toxic effects. Main Outcomes and Measures: The primary end point was 12-month progression-free survival (PFS) rate assessed by investigators according to the Response Evaluation Criteria In Solid Tumors (RECIST), version 1.1. Results: A total of 63 patients (39 female [61.9%]; median age, 60 [range, 47-76] years) were enrolled (full analysis set), and 49 had at least 1 measurable brain lesion (CNS evaluable-for-response set). Median follow-up duration was 28.8 months (95% CI, 27.0-29.8). In the full analysis set, the 12-month PFS rate was 62.1% (95% CI, 48.7-73.0), the median PFS was 20.5 months (95% CI, 12.0-26.9), the 12-month intracranial PFS rate was 76.8% (95% CI, 63.2-85.9), and the median intracranial PFS and overall survival were not reached. Systemic and intracranial objective response rates per RECIST 1.1 were 56 of 63 (88.9% [95% CI, 78.4-95.4]) and 52 of 63 (82.5% [95% CI, 70.9-90.9]) in the full analysis set and 43 of 49 (87.8% [95% CI, 75.2-95.4]) and 42 of 49 (85.7% [95% CI, 72.8-94.1]) in the CNS evaluable-for-response set, respectively. The most common grade 3 or 4 treatment-related adverse event was increased blood creatine phosphokinase (17 participants [27.0%]). No treatment-related deaths occurred. EGFR variant clearance in plasma circulating tumor DNA at day 1 of cycle 2 was independently associated with longer PFS (hazard ratio, 0.14 [95% CI, 0.04-0.47]; P = .001). Conclusions and Relevance: The findings of this nonrandomized clinical trial suggest that high-dose aumolertinib is associated with long-term survival benefit in patients with untreated EGFR-variant NSCLC and brain metastases, with a manageable safety profile. Trial Registration: ClinicalTrials.gov Identifier: NCT04808752.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
JJSA完成签到,获得积分10
1秒前
慕青的应助被SOBER采纳,获得10
1秒前
3秒前
娜比完成签到,获得积分10
3秒前
丘比特的应助被lsq108采纳,获得10
3秒前
4秒前
ZZL发布了新的文献求助10
4秒前
yuyu发布了新的文献求助10
5秒前
8秒前
8秒前
8秒前
在水一方的应助被科研通管家采纳,获得10
8秒前
大模型的应助被科研通管家采纳,获得10
9秒前
彭于晏的应助被科研通管家采纳,获得10
9秒前
我是老大的应助被科研通管家采纳,获得10
9秒前
小蘑菇的应助被科研通管家采纳,获得10
9秒前
Firsterchao的应助被科研通管家采纳,获得10
9秒前
pap发布了新的文献求助10
9秒前
天天快乐的应助被科研通管家采纳,获得10
9秒前
syvshc的应助被科研通管家采纳,获得10
9秒前
9秒前
李健的应助被科研通管家采纳,获得10
10秒前
10秒前
10秒前
Wo了喝完成签到,获得积分10
10秒前
11秒前
Jeremy发布了新的文献求助10
13秒前
wm发布了新的文献求助10
13秒前
水煮电吹风的应助被Luo采纳,获得10
14秒前
小满完成签到 ,获得积分10
14秒前
美好万天完成签到 ,获得积分10
14秒前
科目三的应助被suicone采纳,获得10
15秒前
文静的笑槐完成签到,获得积分10
16秒前
折耳根完成签到,获得积分10
16秒前
坚强孤容发布了新的文献求助10
16秒前
17秒前
十三完成签到 ,获得积分10
17秒前
Fay完成签到 ,获得积分10
17秒前
大白菜完成签到,获得积分10
18秒前
齐胤完成签到,获得积分10
18秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8186806
求助须知:如何正确求助?哪些是违规求助? 9575125
关于积分的说明 21839712
捐赠科研通 7784453
什么是DOI,文献DOI怎么找? 3434839
关于科研通互助平台的介绍 2559245
邀请新用户注册赠送积分活动 2481712